Literature DB >> 7845293

Insomnia in the elderly: its prevalence and correlates in the general population.

S Henderson1, A F Jorm, L R Scott, A J Mackinnon, H Christensen, A E Korten.   

Abstract

OBJECTIVE: To estimate the prevalence of persistent insomnia and its correlates in samples of people living in the community and in institutional settings.
METHODS: Respondents were interviewed in their place of residence by trained interviewers using the Canberra Interview for the Elderly, a structured psychiatric examination.
RESULTS: Information about sleeping habits was obtained from 874 community and 59 institutional residents. Insomnia was persistent in 16% of the community-dwelling population and 12% of the institutional residents, with 15% and 40%, respectively, regularly taking a hypnotic. Of those without insomnia, 10% in the community but over a third in institutions were using a hypnotic. Insomnia was associated with depression, pain and poor physical health.
CONCLUSIONS: Persistent insomnia in the elderly, as in other age groups, is strongly associated with depressed mood, as well as with physical disease. Because of this, insomnia should not be dismissed as a normal part of ageing, and therefore ignored as a significant symptom. Continued surveillance is needed in general practice, geriatric services and nursing homes of the routine use of hypnotics by the elderly.

Entities:  

Mesh:

Year:  1995        PMID: 7845293     DOI: 10.5694/j.1326-5377.1995.tb138406.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  15 in total

Review 1.  Prevalence and treatment of pain in older adults in nursing homes and other long-term care institutions: a systematic review.

Authors:  P L Fox; P Raina; A R Jadad
Journal:  CMAJ       Date:  1999-02-09       Impact factor: 8.262

Review 2.  Use of hydromorphone, with particular reference to the OROS formulation, in the elderly.

Authors:  David Lussier; Ute Richarz; Gabriele Finco
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 3.  Aetiology and treatment of sleep disturbances during perimenopause and postmenopause.

Authors:  P Polo-Kantola; T Saaresranta; O Polo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Insomnia in Elderly Patients: Recommendations for Pharmacological Management.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Drugs Aging       Date:  2018-09       Impact factor: 3.923

5.  Prevalence of insomnia and its relationship to the health habits or status of women living along a city road part 1. epidemiologie study.

Authors:  T Kawada; K Yasuo; S Yosiaki; S Suzuki
Journal:  Environ Health Prev Med       Date:  1997-01       Impact factor: 3.674

6.  OBSERVATION OF THE NATURAL EVOLUTION OF INSOMNIA IN THE AMERICAN GENERAL POPULATION COHORT.

Authors:  Maurice M Ohayon
Journal:  Sleep Med Clin       Date:  2009-03

7.  Sleep disorders and increased risk of subsequent acute coronary syndrome in individuals without sleep apnea: a nationwide population-based cohort study.

Authors:  Wei-Sheng Chung; Cheng-Li Lin; Yung-Fu Chen; John Y Chiang; Fung-Chang Sung; Yen-Jung Chang; Chia-Hung Kao
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

8.  Insomnia, depression, and physical disorders in late life: a 2-year longitudinal community study in Koreans.

Authors:  Jae-Min Kim; Robert Stewart; Sung-Wan Kim; Su-Jin Yang; Il-Seon Shin; Jin-Sang Yoon
Journal:  Sleep       Date:  2009-09       Impact factor: 5.849

9.  Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.

Authors:  Lucie Baillargeon; Philippe Landreville; René Verreault; Jean-Pierre Beauchemin; Jean-Pierre Grégoire; Charles M Morin
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

10.  The assessment and management of insomnia: an update.

Authors:  Andrew D Krystal; Aric A Prather; Liza H Ashbrook
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.